MSTN and chronic obstructive pulmonary disease: In a clinical study of sarcopenic COPD patients, Bimagrumab (an ACVR2 inhibitor that blocks the myostatin pathway) was found to safely increase skeletal muscle mass in patients with COPD, but no improvement in muscle function or physical performance was observed (87).